A novel
biomaterial poly(
ethylene glycol)-block-poly(γ-
cholesterol-
l-glutamate) (
mPEG-PCHLG) was designed and synthesized by introducing
cholesterol side chains into this pegylated poly(
amino acid) copolymers to enlarge the core space to increase the
drug capacity.
Paclitaxel (PTX) loaded
mPEG-PCHLG nanoparticles (PTX-
mPEG-PCHLG-Nps) were developed for the first time. The preparation method of nanoparticles was screened and optimized systemically. The optimal PTX-
mPEG-PCHLG-Nps with the average diameter of 213.71 nm were constructed through the O/W single-
emulsion solvent evaporation method. The entrapment efficiency and
drug loading was 38.02 ± 4.51% and 93.90 ± 4.56%, respectively. PTX-
mPEG-PCHLG-Nps were spherical and well-dispersed and displayed a dramatic sustained-release property. The in vitro cytotoxicity experiments demonstrated that the blank
mPEG-PCHLG nanoparticles had no cytotoxicities on four tumor cell lines including A549, HepG-2, MCF-7 and C26, which implied that
mPEG-PCHLG might be biocompatible. PTX-
mPEG-PCHLG-Nps obtained the same cell growth inhibition activities as free PTX when incubated with the above
tumor cells for 48h. It can be inferred that PTX-
mPEG-PCHLG-Nps could probably have higher anticancer efficacy due to the inadequate release of PTX from nanoparticles. PTX-
mPEG-PCHLG-Nps achieved the highest antitumor activity in A549 rather than HepG-2, MCF-7 and C26, thus PTX-
mPEG-PCHLG-Nps could have a potential application in
lung cancer therapy. All the data indicated that
mPEG-PCHLG was one of biocompatible
biomaterials and worth being widely investigated as hydrophobic
antitumor drug carrier.